Axel-Sven Malkomes
Direttore/Membro del Consiglio presso CELLECTIS S.A.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Axel-Sven Malkomes
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CELLECTIS S.A. | Direttore/Membro del Consiglio | 28/06/2022 | - |
| Independent Dir/Board Member | 28/06/2022 | - | |
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Amministratore Delegato | - | - |
Storia della carriera di Axel-Sven Malkomes
Precedenti posizioni note di Axel-Sven Malkomes
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MEDIGENE AG | Direttore Finanziario/CFO | 01/04/2019 | 31/03/2022 |
| BARCLAYS PLC | Direttore/Membro del Consiglio | 01/03/2016 | 01/03/2019 |
| Corporate Officer/Principal | 01/03/2016 | 01/03/2019 | |
| SOCIÉTÉ GÉNÉRALE | Corporate Officer/Principal | 01/01/2010 | 01/01/2016 |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
 3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Investitore di Private Equity | - | 01/01/2010 |
| MERCK KGAA | Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
| Germania | 5 |
| Francia | 3 |
| Regno Unito | 2 |
Posizioni
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Private Equity Investor | 1 |
Settori
| Health Technology | 5 |
| Finance | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| MEDIGENE AG | Health Technology |
| BARCLAYS PLC | Finance |
| SOCIÉTÉ GÉNÉRALE | Finance |
| MERCK KGAA | Health Technology |
| CELLECTIS S.A. | Health Technology |
| Aziende private | 2 |
|---|---|
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Finance |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
- Borsa valori
- Insiders
- Axel-Sven Malkomes
- Esperienza
